Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza Trivalent Inactivated vaccines Novartis · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Influenza Trivalent Inactivated vaccines Novartis | BIOLOGICAL | Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm. |
| Influenza Trivalent Inactivated vaccines | BIOLOGICAL | Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm. |
Inclusion Criteria: * Children of 6 to \<60 months of age, whose parents/legal guardians have given written informed consent prior to study entry. * In good health as determined by: medical history, physical examination, clinical judgment of the investigator. * Able to comply with all study procedu...
Influenza Trivalent Inactivated vaccines Novartis is an investigational vaccine being developed for the prevention of influenza. It is designed to provide immunity against three strains of the influenza virus. The vaccine is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Influenza Trivalent Inactivated vaccines Novartis is being developed by Novartis AG, a multinational pharmaceutical company headquartered in Switzerland. Novartis is listed on the New York Stock Exchange under the ticker symbol NVS. The vaccine is in Phase 2 clinical trials for influenza.
Influenza Trivalent Inactivated vaccines Novartis is in Phase 2 clinical development. It is an investigational vaccine and has not yet received regulatory approval. The vaccine is being studied for its safety and immunogenicity in healthy children aged 6 to less than 60 months.
Influenza Trivalent Inactivated vaccines Novartis has one completed Phase 2 clinical trial, identified by the National Clinical Trial number NCT00649883. This trial evaluated the safety and immunogenicity of two different doses of the vaccine in healthy children aged 6 to less than 60 months in Guatemala. The trial enrolled 360 participants.
Influenza Trivalent Inactivated vaccines Novartis is a trivalent inactivated vaccine, meaning it contains killed influenza viruses from three strains. When administered, it stimulates the immune system to produce antibodies against these strains, providing protection against seasonal influenza. The vaccine is being developed as a preventive measure for influenza.